Related Experiment Video
Updated: Jun 26, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Current HIV therapeutics: mechanistic and chemical determinants of toxicity
Stephanie K Chiao1, Donna L Romero, Dale E Johnson
1University of California at Berkeley, Department of Nutritional Science & Toxicology, Morgan Hall, CA 94720-3104, USA.
Abstract:
This review discusses current recommendations for initial therapy in HIV-infected individuals and the toxicity of certain components of these therapeutic regimens. In developed regions, therapy is headed in a direction of individualized treatment where AIDS can be converted into a treatable, chronic disease that is characterized by viral loads below assay detection levels. In developing nations, where sophisticated diagnostics are less applicable, treatment continues on a population basis. Because nucleoside reverse transcriptase inhibitors remain a cornerstone of current recommended regimens both in developed and developing regions, the mechanistic and chemical determinants of mitochondrial toxicity are highlighted and discussed in detail.
More Related Videos
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Drug Toxicity: Dose-Dependent Reactions
Retrovirus Life Cycles
Drug Toxicity: Overview
Drug toxicity: Idiosyncratic Reactions
Drug toxicity: Drug–Drug Interaction
Antiviral Nucleoside Inhibitors